Information Provided By:
Fly News Breaks for February 18, 2020
Feb 18, 2020 | 06:27 EDT
Goldman Sachs analyst Ziyi Chen reinstated coverage of BeiGene (BGNE) with a Buy rating and $197.30 price target. The company's positioning as a global biotech with "unique" China access is strengthened with its recent track record in driving global standard R&D and "transformative" deals with Celgene (CELG) and Amgen (AMGN), Chen tells investors in a research note. With zanubrutinib and tislelizumab entering commercial stage and a diversified portfolio, the analyst sees 2020 as a critical year for BeiGene.